A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)Erica Brivio, C. Michel Zwaan, Franco Locatelli et al.|Blood|2020Cited by 93
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22<sup>+</sup> acute lymphoblastic leukemia: results of the phase IB ITCC-059 trialEdoardo Pennesi, C. Michel Zwaan, Erica Brivio et al.|Haematologica|2024Cited by 18
A Phase I Study of Single-Agent Inotuzumab Ozogamicin in Pediatric CD22-Positive Relapsed/Refractory Acute Lymphoblastic Leukemia: Preliminary Results of the ITCC-059 StudyErica Brivio, C. Michel Zwaan, Marta López‐Yurda et al.|Blood|2019Cited by 8
Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059Jen-Hao Wu, Alwin D. R. Huitema, Edoardo Pennesi et al.|Clinical Pharmacokinetics|2024Cited by 6
Sinusoidal Obstruction Syndrome in Children with CD22+ B-Cell Precursors Acute Lymphoblastic Leukemia (BCP-ALL) Treated with Inotuzumab Ozogamicin in Trial ITCC-059: Risk Factors and OutcomesErica Brivio, C. Michel Zwaan, Alba Rubio‐San‐Simón et al.|Blood|2024Cited by 5